Abstract
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identi fiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history.
Similar content being viewed by others
References and Recommended Reading
Gleissner B, Gokbuget N, Bartram CR, et al.: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002, 99:1536–1543.
Dombret H, Gabert J, Boiron JM, et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357–2366.
Goldstone AH, Prentice HG, Durrant J, et al.: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the International ALL Trial (MRC UKALLXII/ECOG E2993) [abstract]. Blood 2001, 98:3556.
Kantarjian HM, O’Brien S, Smith TL, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18(3):547–561.
Avivi I, Goldstone AH: Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 2003, 31:623–632.
Yanada M, Naoe T, Iida H, et al.: Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005, 36:867–872.
Cornelissen JJ, Carston M, Kollman C, et al.: C: Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001, 97:1572–1577.
Kiehl MG, Kraut L, Schwerdtfeger R, et al.: Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816–2825.
Stirewalt DL, Guthrie KA, Beppu L, et al.: Predictors of relapse and overall survival in Philadelphia chromosomepositive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant 2003, 9:206–212.
Esperou H, Boiron JM, Cayuela et al.: A potential graftversus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003, 31:909–918.
Radich J, Gehly G, Lee A, et al.: Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997, 89:2602–2609.
Lee S, Kim DW, Cho B, et al.: Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003, 120:145–153.
Hallbook H, Hagglund H, Stockelberg D, et al.: Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. Bone Marrow Transplant 2005, 35:1141–1148.
Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S: Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: ‘what is the best recipe?’ Bone Marrow Transplant 2005, 36:565–574.
Cimino G, Pane F, Elia L, et al.: The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica 2006, 91:377–380.
Mauro MJ, O’Dwyer ME, Druker BJ: ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy. Cancer Chemother Pharmacol 2001, 48(Suppl 1):S77-S78.
Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640–2653.
Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042. One of the first studies documenting the activity of single-agent imatinib in refractory/relapsed Ph+ ALL (See [19]).
Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965–1971. One of the first studies documenting the activity of single-agent imatinib in refractory/relapsed Ph+ ALL (See [18+]).
Wassmann B, Pfeifer H, Scheuring UJ, et al.: Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood 2004, 103:1495–1498.
Karamlou K, Grant C, Capdeville R, et al.: Kinetics of response to Gleevec in chronic myelogenous leukemia blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia patients [abstract]. Blood 2001, 98:590a.
Scheuring UJ, Pfeifer H, Wassmann B, et al.: Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood 2003, 101:85–90.
Wassmann B, Pfeifer H, Scheuring U, et al.: Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002, 16:2358–2365.
Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999–2007.
Hallbook H, Barbany G, Aleskog A, et al.: In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia. Anticancer Drugs 2005, 16:631–634.
Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407. first study showing the activity of a combined imatinib and standard induction regimen in newly diagnosed Ph + ALL.
Thomas DA, Faderl S, Cortes J, et al.: Outcome with the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract]. Blood 2005, 106:1830.
Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABLpositive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460–466. largest study showing the activity of a combined imatinib and standard induction regimen in newly diagnosed Ph+ ALL.
Linker CA, Levitt LJ, O’Donnell M, et al.: Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991, 78:2814–2822.
Lee KH, Lee JH, Choi SJ, et al.: Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005, 19:1509–1516.
Ottmann OG, Wassmann B, Pfeifer H, et al.: Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (PH+ALL) [abstract]. Blood 2004, 104:685.
Ribera JM, Oriol A, Gonzalez M, et al.: Treatment of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) with Concurrent Chemotherapy and Imatinib Mesylate [abstract]. Blood 2004, 104:4483.
Potenza L, Luppi M, Riva G, et al.: Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission. Haematologica 2005, 90:1275–1277.
Vignetti M, Fazi P, Meloni G, et al.: Dramatic improvement in CR Rate and CR Duration with imatinib in adult and elderly Ph+ ALL patients: results of the GIMEMA prospective study LAL0201 [abstract]. Blood 2004, 10:2739.
Rea D, Legros L, Raffoux E, et al.: High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 2006, 20:400–403.
Lee S, Kim YJ, Min CK, et al.: The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005, 105:3449–3457. first study showing the impact of imatinib on allogeneic HSCT and minimal residual disease detection in newly diagnosed Ph+ ALL.
Dombret H, Witz F, De Botton S, et al.: Imatinib combined with Intensive HAM chemotherapy as consolidation of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+-ALL). Preliminary results of the AFR03 phase I/II study [abstract]. Blood 2004, 104:2741.
Shimoni A, Kroger N, Zander AR, et al.: Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003, 17:290–297.
Zander A, Zabelina T, Renges H, et al.: Pretreatment with Glivec increases transplant-related mortality after allogeneic transplant [abstract]. Blood 2003, 102:1708.
Sohn SK, Kim JG, Kim DH, Lee KB: Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration. Br J Haematol 2003, 121:469–472.
Deininger M, Schleuning M, Greinix H, et al.: The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006, 91:452–459.
Mohty M, Labopin M, Boiron JM, et al.: Reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) for patients with acute lymphoblastic leukemia (ALL): a survey from the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood 2005, 106:659.
Arnold R, Massenkeil G, Bornhauser M, et al.: Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002, 16:2423–2428.
Martino R, Giralt S, Caballero MD, et al.: Allogeneic hematopoietic stem cell transplantation with reducedintensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003, 88:555–560.
Hamaki T, Kami M, Kanda Y, et al.: Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant 2005, 35:549–556.
Passweg JR, Tiberghien P, Cahn JY, et al.: Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998, 21:153–158.
Shin HJ, Chung JS, Cho GJ: Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2005, 36:917–918.
Brandwein JM, Gupta V, Wells RA, et al.: Treatment of elderly patients with acute lymphoblastic leukemia-evidence for a benefit of imatinib in BCR-ABL positive patients. Leuk Res 2005, 29:1381–1386.
Houot R, Tavernier E, Le QH, et al.: Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome. Hematology 2004, 9:369–376.
Annino L, Goekbuget N, Delannoy A: Acute lymphoblastic leukemia in the elderly. Hematol J 2002, 3:219–223.
Pfeifer H, Ottmann OG, Goekbuget N, et al.: A randomized phase II study of single-agent imatinib versus chemotherapy therapy in elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) including analysis of resistance patterns [abstract]. Blood 2005, 106:1824.
Delannoy A, Lhéritier V, Thomas X, et al.: Treatment of Philadelphia-positive acute lymphocytic leukemia (Ph+ ALL) in the elderly with imatinib mesylate (STI571) and chemotherapy [abstract]. Blood 2005, 106:146.
Leis JF, Stepan DE, Curtin PT, et al.: Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004, 45:695–698.
Pfeifer H, Wassmann B, Hofmann et al.: Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003, 9:4674–4681.
Shah NP: Loss of response to imatinib: mechanisms and management. Hematology (Am Soc Hematol Educ Program) 2005:183–187.
Hofmann WK, Jones LC, Lemp NA, et al.: Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002, 99:1860–1862.
Pfeifer H, Wassmann B, Pavlova A, et al.: Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) developing resistance to imatinib [abstract]. Blood, 106:147.
Hu Y, Liu Y, Pelletier S, et al.: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004, 36:453–461.
Ottmann OG, Martinelli G, Dombret H, et al.: A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph + ALL) who are resistant or intolerant to imatinib: the ‘START-L’ CA180015 study [abstract]. Blood 2005, 106:42.
Kantarjian HM, Ottman OG, et al.: AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph + ALL) [abstract]. Blood 2005, 106:37.
Jabbour E, Cortes J, Kantarjian HM, et al.: Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure. Blood 2006. Apr 6; [Epub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kovacsovics, T., Maziarz, R.T. Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact of imatinib treatment on remission induction and allogeneic stem cell transplantation. Curr Oncol Rep 8, 343–351 (2006). https://doi.org/10.1007/s11912-006-0056-y
Issue Date:
DOI: https://doi.org/10.1007/s11912-006-0056-y